Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and produces about $116 million in annual sales.

1. … Alexion Expands Its Rare Disease Pharmaceutical Enterprise …
ALEXION ACQUIRES PORTOLA
PHARMACEUTICALS FOR $1.4
BILLION
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
coveted as the only approved FaxtorXa inhibitor reversal agent
Bare Sky Marketing — Healthcare Content Writing
May 5 · 3 min read
John G. Baresky

2. Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring
Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded
in 2003, Portola is based in South San Francisco and produces about $116
million in annual sales.
As a biotechnology company, Portola specializes in
thrombotic and other hematologic disorders
Portola presently has two primary products. Bevyxxa (betrixaban) is an oral
anticoagulant indicated for the prophylaxis of venous
thromboembolism (VTE) in adult patients hospitalized for an acute medical
illness who are at risk for thromboembolic complications due to moderate or
severe restricted mobility and other risk factors for VTE.1
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a
recombinant modified human factor Xa (FXa) protein indicated for patients
treated with rivaroxaban or apixaban when reversal of anticoagulation is
needed due to life-threatening or uncontrolled bleeding. It is administered
through IV infusion.
Portola’s pipeline candidates include:
• Andexanet Alfa: seeking indications for the reversal of other Factor
Xa inhibitors and urgent surgery
• Cerdulatinib is a dual-spleen tyrosine kinase and janus kinase
(SYK/JAK) inhibitor with potential to gain indications for
peripheral T-cell lymphoma (PTCL), cutaneous T-cell
lymphoma (CTCL) and follicular lymphoma

3. Alexion is a leader centered on the creation of novel,
advanced biotherapies
Headquartered in Boston, Alexion was founded in and generates about $5.5
billion in annual sales. Founded in 1992, they specialize in developing and
commercializing high specialized biotherapeutics and other medicines for
the treatment of rare diseases. Other noteworthy rare disease companies
include Amicus Therapeutics, Biocryst Pharmaceuticals, Healx, Horizon
Therapeutics, Moderna, Regeneron and Ultagenyx.
In April 2020, Alexion launched a phase 3 study to investigate the safety and
efficacy of Ultomiris (ravulizumab-cwvz), a monoclonal antibody C5
inhibitor as a treatment for COVID-19. The product is presently FDA
approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare
blood disease that triggers red blood cells to break apart and release
hemoglobin (the carrier in red blood cells that transports oxygen to cells).
The unique and highly advanced products within Portola’s portfolio and
pipeline are an ideal fit for Alexion’s focus on rare diseases.
Thank you for reading this story
Read my other articles about medical and healthcare business trends,
content marketing and digital strategy, brand and product management,
consumer wellness, managed care and market access strategy. Contact me
today for your healthcare content writing and content strategy needs.

4. I have over 20 years of experience in the healthcare industry producing
valuable healthcare content for audiences and customers spanning
physicians, nurses, pharmacists plus pharmaceutical companies, medical
technology manufacturers, healthcare provider organizations, managed care,
investors, consumers and other stakeholders.
Visit and connect…
Website
LinkedIn
Twitter
Google My Business
As a healthcare content writer, my work aligns with an organization’s voice,
brand, SEO elements, marketplace and objectives. It establishes trust in their
company and recognized value in its products and services that generates
revenue.
This experience was earned through working at Walgreens, Pfizer,
AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and
Boston Software Systems.
To a large degree, my professional interests emulate my family which
includes doctors, nurses, physician assistants and other clinicians plus those
that are working in healthcare administration and commercial enterprises.
•Rare Disease
•Portola

5. •Alexion
•Pharmaceutical
•Mergers And Acquisitions